comparemela.com

Latest Breaking News On - Karin hellsvik - Page 3 : comparemela.com

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader.

United kingdomUnited statesGreg dearbornAdam silversteinPeter kelleherKarin hellsvikAmerican association for cancer researchTherapeutics incFoghorn therapeutics incCompany annual report on formExchange commissionCancer researchAnnual meetingFoghorn eventsGene trafficAnnual report

Foghorn Therapeutics to Participate in Cowen s 44th Annual Health Care Conference

28.02.2024 - CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) - Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today .

Karin hellsvikGreg dearbornAlfonso quintas cardamaPeter kelleherAdam silversteinFoghorn therapeutics incFoghorn presenterChief medical officerGene traffic controlFoghorn therapeuticsLifesci advisors

Foghorn Therapeutics Announces CFO Departure

CAMBRIDGE, Mass., Jan. 03, 2024 Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene.

United kingdomGreg dearbornAllan reineHans vitzthumKarin hellsvikAdrian gottschalkMichael lampeExchange commissionFoghorn therapeutics incTherapeutics incCompany annual report on formChief financial officerChief executive officerGene trafficAnnual reportFoghorn therapeutics

Foghorn Therapeutics Announces CFO Departure

Foghorn Therapeutics Announces CFO Departure
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomMichael lampeKarin hellsvikAdrian gottschalkGreg dearbornAllan reineHans vitzthumExchange commissionFoghorn therapeutics incCompany annual report on formTherapeutics incChief financial officerChief executive officerGene trafficAnnual reportFoghorn therapeutics

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Dec. 01, 2023 Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene.

United statesUnited kingdomSan diegoCourtneyd dinardoHans vitzthumMichael lampeGreg dearbornKarin hellsvikCompany annual report on formUniversity of texas md anderson cancer centerExchange commissionTherapeutics incAmerican society of hematologyFoghorn therapeutics incAmerican societyAnnual meeting

vimarsana © 2020. All Rights Reserved.